GSK.L: Summary for GLAXOSMITHKLINE PLC ORD 25P - Yahoo Finance

UK Markets close in 6 hrs 15 mins

GlaxoSmithKline plc (GSK.L)


LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1,666.50-4.00 (-0.24%)
As of 9:59AM GMT. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous close1,670.50
Open1,671.00
Bid1,666.50 x 175400
Ask1,667.00 x 417900
Day's range1,663.00 - 1,676.17
52-week range1,363.00 - 1,745.56
Volume1,392,293
Avg. volume7,579,878
Market cap80.89B
Beta1.20
PE ratio (TTM)89.60
EPS (TTM)N/A
Earnings dateN/A
Dividend & yield1.01 (4.89%)
Ex-dividend dateN/A
1y target estN/A
  • The Wall Street Journal5 hours ago

    [$$] AT&T, Verizon Pull Ads From Google Over ‘Hate’ Videos

    AT&T and Verizon Communications pulled much of their advertising from Google over concerns that their ads may have run alongside controversial videos, extending the financial impact of a controversy.

  • Reuters - UK Focus10 hours ago

    GSK and Regeneron to mine gene data from 500,000 Britons

    Britain's GlaxoSmithKline (Amsterdam: GO8.AS - news) and U.S.-based Regeneron Pharmaceuticals (NasdaqGS: REGN - news) are embarking on a joint project with UK Biobank, the world's most detailed biomedical database, to hunt for new clues linking genes and disease. By analysing genetic variations and health in 500,000 middle-aged and older Britons, the partners said on Thursday they hoped to identify promising leads for new medicines. The aim is to analyse DNA from an initial 50,000 samples by the end of 2017, using Regeneron's large gene sequencing centre in New York.

  • Reuters10 hours ago

    GSK and Regeneron to mine gene data from 500,000 Britons

    Britain's GlaxoSmithKline and U.S.-based Regeneron Pharmaceuticals are embarking on a joint project with UK Biobank, the world's most detailed biomedical database, to hunt for new clues linking genes and disease. By analysing genetic variations and health in 500,000 middle-aged and older Britons, the partners said on Thursday they hoped to identify promising leads for new medicines. The aim is to analyse DNA from an initial 50,000 samples by the end of 2017, using Regeneron's large gene sequencing centre in New York.